Pfizer gives Nektar $135M for Exubera settlement
Nektar Therapeutics got a consolation prize of $135 million from Pfizer--and a fresh shot at signing a new partner--to calm any upset feelings about Pfizer's abandonment of Exubera, a once mighty prospect in the world of inhalable diabetes therapies. In return, both parties are absolved of any further obligations for Exubera or the next-generation version of the therapy that Nektar has in Phase I. And if Nektar lines up a new partner, Pfizer has agreed to hand over any rights it has in the two products.
- check out Pfizer's release
- here's the report on Nektar from RTT News
Related Articles:
Pfizer kills off Exubera, hunts for deals. Report
Exubera becoming a big disappointment for Pfizer. Report
UK: Exubera not worth the price. Report
FDA approves Pfizer's inhaled insulin. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets